New Hope for Preventing Postoperative Delirium in Elderly Surgical Patients
A recent randomized, triple-blind, placebo-controlled trial suggests that an intranasal form of dexmedetomidine administered the night before surgery can significantly reduce the incidence of postoperative delirium (POD) in elderly patients with pre-existing sleep disorders. The study, conducted at The Affiliated Hospital of Guizhou Medical University, focused on patients undergoing major noncardiac surgery, a population particularly vulnerable to this acute form of brain dysfunction. This finding is critical because POD is associated with prolonged hospital stays, increased complications, higher readmission rates, and long-term cognitive decline, placing substantial burdens on patients and healthcare systems.
Postoperative delirium is a common acute neuropsychiatric syndrome affecting up to 23.8% of individuals aged 60 and older after major noncardiac surgery. It manifests as acute disturbances in attention, awareness, cognition, and sleep-wake cycles. Preoperative sleep disturbances are recognized as a significant, modifiable risk factor, with more than 60% of older adults experiencing poor sleep prior to major surgical procedures. Addressing this modifiable factor could significantly improve patient outcomes.
The Study and Its Approach
The trial, registered with the China Clinical Trial Registry, involved 348 elderly patients, all randomized into either a dexmedetomidine or placebo group. Participants were required to be aged 60 or older, scheduled for major noncardiac surgery lasting at least two hours, and have a Pittsburgh Sleep Quality Index (PSQI) score greater than 7, indicating pre-existing sleep disorders. Exclusions included known allergies to the study drug, severe heart conditions, diagnosed sleep apnea, or existing neurological or psychiatric disorders.
The intervention involved administrating either dexmedetomidine hydrochloride nasal spray or an identical-looking placebo (sterile 0.9% saline) the night before surgery. Dosing was meticulously adjusted based on body weight, with a rescue dose available if patients did not fall asleep within 30 minutes, aligning with the expected peak plasma concentration of intranasal dexmedetomidine. The triple-blind design ensured that participants, perioperative care teams, and outcome assessors were unaware of who received the active drug versus placebo. Adherence to a quiet, darkened environment with minimal disruptions was enforced to promote undisturbed sleep.
Key Findings: Reduced Delirium and Improved Sleep
The primary outcome, the incidence of POD within five days post-surgery, showed a statistically significant reduction in the dexmedetomidine group. Only 18.4% of patients receiving dexmedetomidine experienced POD, compared to 32.8% in the placebo group. This represents a relative risk of 0.56, indicating a substantial benefit. Notably, the reduction was even more pronounced for moderate to severe POD, decreasing from 20.7% in the placebo group to 8.6% in the dexmedetomidine group. While exploratory analyses of delirium subtypes (hypoactive, hyperactive, mixed) also showed trends toward lower incidence in the active treatment group, these were not statistically significant due to limited case numbers in each subtype.
Objective and subjective sleep metrics collected the night before surgery revealed significant improvements with dexmedetomidine. Patients in the active group experienced an average of 0.89 hours more total sleep time, demonstrating better sleep efficiency, fewer awakenings, and reduced sleep latency, as measured by wearable devices. Subjectively, participants also reported better sleep quality. These findings underscore the potential role of dexmedetomidine’s sleep-promoting properties in mitigating POD risk.
Safety Profile and Other Outcomes
While effective, the intervention was associated with an increased incidence of bradycardia (slow heart rate) in the dexmedetomidine group (37.9% vs. 16.7% in the placebo group). However, these events were managed by predefined protocols, and no significant differences were observed in serious adverse events between the two groups. Heart rate and mean arterial pressure were transiently lower in the dexmedetomidine group during the initial hours post-administration, consistent with the drug’s known pharmacology. No significant effects on peripheral oxygen saturation were noted.
Other secondary outcomes, including delayed neurocognitive recovery (dNCR) on postoperative days 7 and 30, postoperative pain scores, and non-delirium complications, did not show statistically significant differences. Though there was a tendency for lower dNCR incidence in the dexmedetomidine group, further research is needed to solidify this observation. Similarly, while a statistically significant difference was observed in resting pain scores on day 3, it did not cross the threshold for clinical significance. Hospital length of stay and 30-day mortality rates remained comparable between groups.
Implications for Clinical Practice and Future Research
This study provides compelling evidence that preoperative intranasal dexmedetomidine can offer a meaningful reduction in POD incidence for a high-risk elderly population with pre-existing sleep disorders. The intervention harnesses the drug’s pharmacological benefits in a practical, ward-feasible manner, addressing a critical gap in delirium prevention strategies. The sleep-promoting effects of dexmedetomidine, particularly its potential to enhance clearance of inflammatory factors and metabolic waste in the brain, may be a key mechanism behind its protective effect against delirium, as supported by findings in BMC Anesthesiology and Nature and Science of Sleep. This is particularly relevant as sleep disturbances are significant factors in cognitive impairment and delirium, according to a systematic review published in Frontiers in Psychiatry.
However, the increased incidence of bradycardia necessitates careful patient selection and vigilant cardiovascular monitoring. This implies that while promising, routine adoption would require robust multi-center confirmatory trials, with a focus on comprehensive handling of missing data, adjudicated harms, and appropriate cognitive endpoints. Further investigation into optimal dosing strategies, the duration of benefits, and the underlying neurobiological mechanisms is also warranted. Read more on Globally Pulse Health about advances in delirium prevention and management.
